Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $122 from $120 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 sales/EPS beat and raised FY25 guidance by $9.5M. Management provided preliminary FY26 sales outlook bracketing consensus. Wells raised its Epioxa and iDose estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Strong Buy Rating for Glaukos Driven by iDose Success and Positive Revenue Projections
- Glaukos’s Strong Growth Prospects: Buy Rating Affirmed Amid Surpassing Sales and Promising Pipeline
- Glaukos Corp. Reports Record Q3 Sales Growth
- Closing Bell Movers: Meta sinks, Alphabet jumps after earnings
- Glaukos Reports Record Q3 2025 Sales Growth